Mentions
Extended reach
Total likes
Video views
AI synopsis
The overall tone reflects skepticism about new data, citing phrases like 'not supported by evidence' and 'current recommendations remain unchanged,' which emphasize the perceived lack of impact. Posts referencing official statements and systematic critiques highlight the persistent doubts about pharmacogenomic tools in depression treatment.
Most comments clearly express disagreement with the efficacy of pharmacogenomic tools for depression, emphasizing lack of supportive evidence.
The discussions show limited curiosity, mostly reiterating official conclusions rather than exploring new perspectives.
Some posts delve into methodological critiques and interpretational issues, reflecting basic engagement.
The general consensus suggests the findings reinforce current guidelines, with limited perceived groundbreaking influence.
Evidence still does not support the routine use of pharmacogenomic testing as routine guidance to antidepressant selection in adults with major depression https://t.co/gF4Vk5TDmL
Me preguntó hace unos días un paciente que si le mandaba a realizar estudio #Farmacogenético para ver que medicamento le funcionaría mejor para su #Depresión Mi respuesta: "No hay evidencia que eso nos resuelva ni nos indique hacia donde movernos" https://t.co/GGUfC5gY8q"
New data do not alter the 2018 recommendations. Current evidence does not support the use of currently available PGx tools for the treatment of MDD. Pharmacogenomic Clinical Support Tools for the Treatment of Depression | American Journal of Psychiatry https://t.co/UKzHPMghqI
New data do not alter 2018 recommendations from the @APApsychiatric Council of Research Workgroup on Biomarkers and Novel Treatments that current research does not support the use of genetic tools in treatment selection for major depressive disorder. https://t.co/FaOKbVBKRm https://t.co/VipWr2LmQw
Review: Actual evidence does not support the use of currently available combinatorial pharmacogenomic tools for treatment selection in MDD https://t.co/toip5bOZUR
Grand Rounds for April 13, 2023 Matthew Baum, MD, PhD, D.Phil TITLE: “Update on pharmacogenomic clinical support tools for the treatment of depression” Kelly Brown, MD TITLE: “Core Clinical Experiences in General Psychiatry Training” https://t.co/2LcON4OHcL
American Journal of Psychiatry Deputy Editor Daniel S Pine MD discusses the article Pharmacogenomic Clinical Support Tools for the Treatment of Depression by Matthew L Baum MD PhD and colleagues. The review updates 2018…
American Journal of Psychiatry Deputy Editor Daniel S Pine MD discusses recent research on pharmacogenomic tools in depression treatment, highlighting new trials and meta-analyses from 2017 to 2022. Current evidence…
https://t.co/N39jbxTBpz I'm finding PGx testing is broadly not supported by either evidence or methodology...
RT @carlos_arnaud: Me preguntó hace unos días un paciente que si le mandaba a realizar estudio #Farmacogenético para ver que medicamento le…
Herramientas de apoyo clínico farmacogenómico para el tratamiento de la depresión https://t.co/wZT4wWrFnZ
RT @carlos_arnaud: Me preguntó hace unos días un paciente que si le mandaba a realizar estudio #Farmacogenético para ver que medicamento le…
Me preguntó hace unos días un paciente que si le mandaba a realizar estudio #Farmacogenético para ver que medicamento le funcionaría mejor para su #Depresión Mi respuesta: "No hay evidencia que eso nos resuelva ni nos indique hacia donde movernos" https://t.co/GGUfC5gY8q"
RT @rogersmcintyre: Evidence still does not support the routine use of pharmacogenomic testing as routine guidance to antidepressant selec…
RT @rogersmcintyre: Evidence still does not support the routine use of pharmacogenomic testing as routine guidance to antidepressant selec…
3. “Pharmacogenomic Clinical Support Tools for the Treatment of Depression,” by Matthew L. Baum, M.D., Ph.D., et al. 3/4 https://t.co/0IJzo8pYBV
RT @rogersmcintyre: Evidence still does not support the routine use of pharmacogenomic testing as routine guidance to antidepressant selec…
RT @rogersmcintyre: Evidence still does not support the routine use of pharmacogenomic testing as routine guidance to antidepressant selec…
RT @rogersmcintyre: Evidence still does not support the routine use of pharmacogenomic testing as routine guidance to antidepressant selec…
RT @rogersmcintyre: Evidence still does not support the routine use of pharmacogenomic testing as routine guidance to antidepressant selec…
RT @rogersmcintyre: Evidence still does not support the routine use of pharmacogenomic testing as routine guidance to antidepressant selec…
RT @rogersmcintyre: Evidence still does not support the routine use of pharmacogenomic testing as routine guidance to antidepressant selec…
RT @rogersmcintyre: Evidence still does not support the routine use of pharmacogenomic testing as routine guidance to antidepressant selec…
RT @rogersmcintyre: Evidence still does not support the routine use of pharmacogenomic testing as routine guidance to antidepressant selec…
RT @rogersmcintyre: Evidence still does not support the routine use of pharmacogenomic testing as routine guidance to antidepressant selec…
RT @rogersmcintyre: Evidence still does not support the routine use of pharmacogenomic testing as routine guidance to antidepressant selec…
RT @rogersmcintyre: Evidence still does not support the routine use of pharmacogenomic testing as routine guidance to antidepressant selec…
RT @rogersmcintyre: Evidence still does not support the routine use of pharmacogenomic testing as routine guidance to antidepressant selec…
RT @rogersmcintyre: Evidence still does not support the routine use of pharmacogenomic testing as routine guidance to antidepressant selec…
RT @rogersmcintyre: Evidence still does not support the routine use of pharmacogenomic testing as routine guidance to antidepressant selec…
RT @rogersmcintyre: Evidence still does not support the routine use of pharmacogenomic testing as routine guidance to antidepressant selec…
Evidence still does not support the routine use of pharmacogenomic testing as routine guidance to antidepressant selection in adults with major depression https://t.co/gF4Vk5TDmL
Review: Actual evidence does not support the use of currently available combinatorial pharmacogenomic tools for treatment selection in MDD https://t.co/toip5bOZUR
RT @DrDanielGih: New data do not alter the 2018 recommendations. Current evidence does not support the use of currently available PGx tools…
RT @DrDanielGih: New data do not alter the 2018 recommendations. Current evidence does not support the use of currently available PGx tools…
New data do not alter the 2018 recommendations. Current evidence does not support the use of currently available PGx tools for the treatment of MDD. Pharmacogenomic Clinical Support Tools for the Treatment of Depression | American Journal of Psychiatry https://t.co/UKzHPMghqI
RT @APAPubJournals: New data do not alter 2018 recommendations from the @APApsychiatric Council of Research Workgroup on Biomarkers and Nov…
Review: The evidence does not support the use of currently available combinatorial pharmacogenomic tools for treatment selection in MDD. Priority efforts include fully blinded study designs and inclusion of promising genetic variants https://t.co/toip5bOZUR
New data do not alter 2018 recommendations from the @APApsychiatric Council of Research Workgroup on Biomarkers and Novel Treatments that current research does not support the use of genetic tools in treatment selection for major depressive disorder. https://t.co/FaOKbVBKRm https://t.co/VipWr2LmQw
Grand Rounds for April 13, 2023 Matthew Baum, MD, PhD, D.Phil TITLE: “Update on pharmacogenomic clinical support tools for the treatment of depression” Kelly Brown, MD TITLE: “Core Clinical Experiences in General Psychiatry Training” https://t.co/2LcON4OHcL
DOI: 10.1176/appi.ajp.20230657 · Clinical Trial Follow-up: Antenatal corticosteroids not associated with adverse neurodevelopmental outcomes in late preterm ...
DOI: 10.1176/appi.ajp.20230657. 1 2 … 119 Next. LinksMedicus. About Us · Terms of Use · Privacy Policy · Google Translate Disclaimer. Updates. Via Telegram ...
DOI: 10.1176/appi.ajp.20230657 · Phase 1-2 Study: Safety and efficacy of EDIT-101 CRISPR-Cas9 treatment for CEP290-associated retinal degeneration – N Engl J ...
DOI: 10.1176/appi.ajp.20230657 · Guidelines on the use of intravenous albumin in various clinical settings – CHEST. 25 May, 2024 | 18:49h | UTC. The ...
The FDA and psychiatric groups do not recommend using them. https://psychiatryonline.org/doi/10.1176/appi.ajp.20230657 · everlasting_torment. • ...
https://www.psychiatryonline.org/doi/10.1176/appi.ajp.20230657. No. And you should stop doing them. It's a waste of money and resources ...
https://www.psychiatryonline.org/doi/10.1176/appi.ajp.20230657. The American Association of Psychiatry published a stance against gene ...
https://www.psychiatryonline.org/doi/10.1176/appi.ajp.20230657. Amerikan Psikiyatri Birliği 2018'de genetik testlere karşı bir duruş ...
https://www.psychiatryonline.org/doi/10.1176/appi.ajp.20230657. Den Amerikanska Psykiatriföreningen publicerade en ståndpunkt mot gentestning ...
org/doi/10.1176/appi.ajp.20230657. 미국 정신의학 협회는 2018년에 유전자 검사에 반대하는 입장을 발표했고, 올해 연구를 업데이트해서 입장을 ...
" https://psychiatryonline.org/doi/10.1176/appi.ajp.20230657 · Like · Reply · 19 Reactions 20 Reactions. Liz Collins, graphic · Liz Collins.
DOI: 10.1176/appi.ajp.20230657. Join LinksMedicus' Telegram Channels and WhatsApp Alerts for personalized updates in your specialty. We ...
... AJP in Advance (doi: 10.1176/appi.ajp.20230657). This conclusion is entirely consistent with the CPIC (Clinical Pharmacogenetics ...
RF
DA
DM
JA
P
BR
T
N
D
DD
A
دا
SM
OS
JK
RL
TG
AY
DM
EP
LR
JF
RS
TB
MM
RH
C
TH
BM